Lilly Q1 Beat, Koundeo Launch Spurs Growth

Introduction

Eli Lilly (LLY) posted a decisive start to 2026: a substantial Q1 beat, a higher full-year outlook, and tangible early uptake for its oral GLP‑1 obesity therapy, Koundeo. Last week’s developments were concrete — not speculative — and combine to strengthen near-term revenue visibility while accelerating long-term pipeline diversification through AI partnerships and targeted acquisitions.

Quarterly results and raised guidance

Revenue, earnings and shareholder returns

In Q1 2026 Lilly reported revenue of $19.8 billion, with reported EPS of $8.26 and non‑GAAP EPS of $8.55. Management raised full‑year revenue guidance to $82–$85 billion and non‑GAAP EPS to $35.50–$37.00. Capital deployment remained solid: the company returned $1.5 billion via dividends and repurchased $2.4 billion of stock during the quarter.

Koundeo launch and payer support

Koundeo (oral orforglipron) launched April 9 and reached more than 20,000 treated patients in the early weeks. Management reported that roughly 80% of those patients were new to the GLP‑1 class and that over 8,000 prescribers have written scripts — an early adoption signal that complements Lilly’s injectable franchise. Importantly, Medicare extended a program that caps senior out‑of‑pocket spending on designated obesity therapies at $50 per month from July 1, 2026, through December 2027. That payer support materially reduces potential affordability barriers for a high‑value, large‑addressable product and directly supports uptake projections for Lilly’s obesity portfolio.

Pipeline acceleration: AI deals and targeted M&A

Insilico collaboration: AI-driven discovery

Lilly expanded its AI-driven discovery strategy with a collaboration with Insilico Medicine. The agreement includes approximately $115 million upfront and potential milestones that can reach roughly $2.75 billion. The deal targets preclinical oral therapeutics across multiple therapeutic areas and underscores Lilly’s push to accelerate early discovery and diversify modalities using computational platforms.

Bolt-on acquisitions

To broaden its pipeline, Lilly announced several bolt‑on transactions during the quarter, including deals for Orna Therapeutics, Centessa Pharmaceuticals, Colonia Therapeutics, and Ajax Therapeutics. These acquisitions add RNA, targeted oncology, and precision‑medicine capabilities — complementing Lilly’s core strengths in metabolic and immunologic drugs while expanding optionality in areas with high unmet need.

Implications for LLY stock

The combination of a strong quarterly beat, raised guidance, early commercial traction for Koundeo, payer cost‑sharing support for seniors, strategic AI investment, and selective M&A creates multiple, measurable drivers for revenue and margin expansion. In aggregate, these factors reinforce investor confidence in Lilly’s ability to sustain growth beyond its established injectable GLP‑1 franchise and increase the probability that new modalities will contribute meaningfully over the next several years.

Short‑term stock performance will remain sensitive to execution on Koundeo supply and prescribing trends, integration milestones for acquisitions, and the cadence of milestone recognition from discovery partnerships. However, last week’s developments reduce headline risk by replacing speculation with quantifiable adoption and financial metrics.

Conclusion

Last week’s concrete developments for Eli Lilly — a clear Q1 beat and upgrade, substantive early uptake for Koundeo aided by expanded Medicare cost support, plus strategic investments in AI and targeted acquisitions — strengthen both near‑term revenue visibility and long‑term pipeline optionality. For investors focused on the healthcare sector, these are measurable catalysts that support Lilly’s leadership in metabolic therapies while broadening its therapeutic footprint.